ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII), announces the first patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company’s 360° Clinical Series. The CALCIUM 360° study will evaluate the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI’s Diamondback 360® PAD System, a minimally invasive catheter for treating PAD anywhere in the leg. The first procedure was performed successfully by Dr. Nicolas Shammas at Trinity Medical Center, Bettendorf, Iowa. Dr. Shammas is the research director of the Midwest Cardiovascular Research Foundation in Iowa. He and Dr. Russell Lam, Presbyterian Hospital, Dallas, are the study’s co-principal investigators.
